Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer

10/25/2021 | 01:00am EST

ERYTECH Pharma announced top-line results from its Phase 3 TRYbeCA-1 clinical trial evaluatingeryaspase as second-line treatment in 512 patients with metastatic pancreatic cancer. The trial did not meet its primary endpoint of overall survival (OS). In the TRYbeCA-1 trial, eryaspase demonstrated an improvement in the primary endpoint of OS compared to chemotherapy alone with a hazard ratio (HR) of 0.92 (95% confidence interval (CI), 0.76-1.11) in the intent-to-treat population, and the difference was not statistically significant (p-value 0.375). The median OS for patients treated with eryaspase plus chemotherapy was 7.5 months (95% CI, 6.5-8.3), compared to 6.7 months (95% CI, 5.4-7.5) for chemotherapy alone. Interestingly, while the patients treated with gemcitabine plus nabpaclitaxel did not experience a survival benefit from the addition of eryaspase, patients treated with eryaspase and an irinotecan-based chemotherapy regimen showed nominal survival benefit with a HR of 0.77 (95% CI, 5.7-1.05) over those treated with chemotherapy alone. This prespecified subgroup had a median OS of 8.0 months in the eryaspase-treated arm versus 5.7 months in the control arm (per protocol population). Key secondary endpoints of the trial, including progression-free survival, disease control rate and objective response rate, showed benefit in favor of eryaspase. The safety profile of eryaspase observed in the TRYbeCA-1 trial was consistent with earlier observations and previous safety reviews by the trial?s independent data monitoring committee (IDMC). ERYTECH will now focus on its late-stage program in acute lymphoblastic leukemia (ALL) and pursue a path to approval in hypersensitive ALL based on positive results of NOPHO-sponsored Phase 2 trial. The Company reiterates its intention to submit a BLA before the end of the year.


ę S&P Capital IQ 2021
All news about ERYTECH PHARMA S.A.
11/29Erytech Pharma Gets US Patent For Methioninase, Asparaginase in Solid Tumor Treatment
MT
11/29Erytech Pharma Secures US Patent in Methioninase, Asparaginase Use for Solid Tumors -- ..
MT
11/29ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase aga..
AQ
11/17European ADRs Higher Wednesday as Credit Suisse, Barrick Gold Gain
MT
11/16European ADRs Mixed in Tuesday Morning Trading
MT
11/15ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
AQ
11/15European ADRs Move Slightly Higher in Monday Trading
MT
11/15ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematolo..
GL
11/12European ADRs Move Lower in Friday Trading
MT
11/11GLOBAL MARKETS LIVE : Daimler, Delivery Hero, Foxconn, China Evergrande, Kraft Heinz...
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2021 6,74 M 7,61 M 7,61 M
Net income 2021 -61,2 M -69,2 M -69,2 M
Net Debt 2021 16,1 M 18,2 M 18,2 M
P/E ratio 2021 -0,69x
Yield 2021 -
Capitalization 59,6 M 67,2 M 67,4 M
EV / Sales 2021 11,2x
EV / Sales 2022 6,58x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 2,14 €
Average target price 4,30 €
Spread / Average Target 101%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-69.97%67
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.27.38%64 416
VERTEX PHARMACEUTICALS-22.32%46 678